Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tenaya Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Tenaya Therapeutics, Inc.’s stock price such as:

• Tenaya Therapeutics, Inc.’s current stock price and volume
• Why Tenaya Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TNYA from analysts
• TNYA’s stock price momentum as measured by its relative strength

About Tenaya Therapeutics, Inc. (TNYA)

Before we jump into Tenaya Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Want to learn more about Tenaya Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tenaya Therapeutics, Inc..

Tenaya Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 11:33 AM, CST, Tenaya Therapeutics, Inc.’s stock price was $1.392.

Tenaya Therapeutics, Inc. is up 2.38% from its previous closing price of $1.360.

During the last market session, Tenaya Therapeutics, Inc.’s stock traded between $1.360 and $1.430. Currently, there are approximately 163.35 million shares outstanding for Tenaya Therapeutics, Inc..

Tenaya Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tenaya Therapeutics, Inc. Stock Price History

Tenaya Therapeutics, Inc.’s (TNYA) price is currently down 3.31% so far this month.

During the month of November, Tenaya Therapeutics, Inc.’s stock price has reached a high of $1.560 and a low of $1.150.

Over the last year, Tenaya Therapeutics, Inc. has hit prices as high as $4.010 and as low as $0.360. Year to date, Tenaya Therapeutics, Inc.’s stock is down 2.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tenaya Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there were 0 analysts who downgraded Tenaya Therapeutics, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Tenaya Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tenaya Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tenaya Therapeutics, Inc. (TNYA) by visiting AAII Stock Evaluator.

Relative Price Strength of Tenaya Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Tenaya Therapeutics, Inc. has a weighted four-quarter relative price strength of 6.61%, which translates to a Momentum Score of 77 and is considered to be Strong.

Want to learn more about how Tenaya Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tenaya Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, Tenaya Therapeutics, Inc.’s stock price is $1.392, which is up 2.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tenaya Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.